177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

被引：19
|
作者：
Assadi, Majid [1 ]
Pirayesh, Elahe [2 ]
Rekabpour, Seyed Javad [3 ]
Zohrabi, Farshad [4 ]
Jafari, Esmail [1 ]
Nabipour, Iraj [5 ]
Esmaili, Abdolhamid [6 ]
Amini, Abdullatif [7 ]
Ahmadzadehfar, Hojjat [8 ]
机构：
[1] Bushehr Univ Med Sci, Bushehr Med Univ Hosp, Persian Gulf Nucl Med Res Ctr, Dept Mol Imaging & Radionuclide Therapy,Fac Med, Bushehr, Iran
[2] Shahid Beheshti Univ Med Sci, Shohada & Tajrish Med Ctr, Dept Nucl Med, Tehran, Iran
[3] Bushehr Med Univ Hosp, Dept Oncol, Bushehr, Iran
[4] Bushehr Med Univ Hosp, Dept Urol, Bushehr, Iran
[5] Bushehr Med Univ Hosp, Dept Internal Med, Div Endocrinol, Bushehr, Iran
[6] Bushehr Med Univ Hosp, Dept Pathol, Bushehr, Iran
[7] Bushehr Univ Med Sci, Dept Cardiol, Bushehr Heart Med Ctr, Bushehr, Iran
[8] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
来源：
CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 12期
关键词：
prostate cancer; neuroendocrine differentiation; Lu-177-PSMA; Lu-177-DOTATATE; GA-68-PSMA; MEDICINE;
D O I：
10.1097/RLU.0000000000002824
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
We presented a promising result of radionuclide therapy using Lu-177-PSMA and Lu-177-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.
引用
收藏
页码：978 / 980
页数：3
相关论文
共 50 条
  • [31] Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand
    Sundset, Rune
    Haugnes, Hege Sagstuen
    Perez, Alexander
    Engelsen, Ola
    Fosseide, Ida H. H.
    Castillejo, Miguel J.
    Bogsrud, Trond Velde
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (09)
  • [32] 177Lu-PSMA Radioligand Therapy for Prostate Cancer
    Fendler, Wolfgang P.
    Rahbar, Kambiz
    Herrmann, Ken
    Kratochwil, Clemens
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (08) : 1196 - 1200
  • [33] Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing 177Lu-PSMA Therapy
    Ahmadzadehfar, Hojjat
    Essler, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (07) : 1033 - 1034
  • [34] Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
    von Eyben, Finn Edler
    Roviello, Giandomenico
    Kiljunen, Timo
    Uprimny, Christian
    Virgolini, Irene
    Kairemo, Kalevi
    Joensuu, Timo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 496 - 508
  • [35] Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
    Finn Edler von Eyben
    Giandomenico Roviello
    Timo Kiljunen
    Christian Uprimny
    Irene Virgolini
    Kalevi Kairemo
    Timo Joensuu
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 496 - 508
  • [36] Lu-177 PSMA Radioligand Therapy as Salvage Treatment in Metastatic Castration-Resistant Prostate Cancer
    Kulkarni, H. R.
    Singh, A.
    Schuchardt, C.
    Langbein, T.
    Zhang, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S287 - S288
  • [37] Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
    Wenzel, Mike
    Koll, Florestan
    Hoeh, Benedikt
    Humke, Clara
    Siech, Carolin
    Mader, Nicolai
    Sabet, Amir
    Groener, Daniel
    Steuber, Thomas
    Graefen, Markus
    Maurer, Tobias
    Brandts, Christian
    Banek, Severine
    Chun, Felix K. H.
    Mandel, Philipp
    JOURNAL OF NUCLEAR MEDICINE, 2025, 66 (01) : 61 - 66
  • [38] Patient-specific pharmacokinetics and dosimetry over multiple therapy cycles during 177Lu-based radionuclide therapy: a study for 177Lu-DOTATATE and 177Lu-PSMA
    Gosewisch, A.
    Ermoschkin, L.
    Ilhan, H.
    Todica, A.
    Vamacka, L.
    Bartenstein, P.
    Boening, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S270 - S271
  • [39] Liver Enzyme Elevation After 177Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer
    Treiber, Hannes
    Koenig, Alexander
    Neesse, Albrecht
    Richter, Annika
    Sahlmann, Carsten Oliver
    Strauss, Arne
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (07) : 1016 - 1019
  • [40] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
12345